syndromes to varying degrees. It was not until 2004 that this combined syndrome was found to be associated with a mutation in the SMAD4 gene (7) . In addition to the previously mentioned fi ndings, these patients are more likely to develop early onset colorectal cancer (CRC; mean age 28 years) and have a higher rate of anemia than HHT patients with other mutations (11) . Herein we describe a patient with this combined syndrome, JP and HHT, who presented to our emergency department. Proband's father and paternal grandfather both had colon polyps, arteriovenous malformations (AVMs), and nosebleeds, while her maternal lineage was unremarkable for juvenile polyposis syndrome or hereditary hemorrhagic telangiectasia (HHT). These results suggest that the patient's putative SMAD4 mutation was paternally inherited.
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CASE REPORT
A 27-year-old woman presented to the emergency room at Baylor University Medical Center at Dallas with complaints of diarrhea, fatigue, hematochezia, nausea, vomiting, and abdominal pain. She had been experiencing these symptoms on and off for years with a progressive worsening of her symptoms. Her past medical history was signifi cant for intermittent small bowel obstructions and gastrointestinal bleeding requiring a laparotomy with intraoperative enteroscopy and resection of three "infl ammatory polyps." She also had a history of epistaxis and chronic iron defi ciency anemia with low levels of albumin requiring frequent blood transfusions. She complained that she had been "sick all of her life." Early in 2011, she had been treated with steroids, azathioprine, and infl iximab for Crohn's disease, but she showed no improvement in symptoms. Her family history included a father with a "large AVM in his head" and nosebleeds and a paternal grandfather who had "AVMs" and died of a "heart attack" in his mid 50s (Figure 1) .
Th e patient appeared chronically ill and had Cushingoid features. She had clubbing of the fi ngers and toes (Figure 2) , an abdominal bruit, diff use abdominal tenderness to palpation, and one single, small telangiectasia on her lip. Bone marrow biopsy indicated the patient had an iron defi ciency anemia. Th ough a more remote computed tomography (CT) scan showed terminal ileal thickening suggestive of Crohn's disease, a CT enterography revealed numerous nodular polypoid arterial enhancing lesions of the distal and terminal ileum, a markedly enlarged hepatic artery as can be seen with HHT, and small subcapsular foci of liver enhancement suggestive of hepatic AVMs (Figure 3 ), which were later shown to be AVMs on hepatic magnetic resonance imaging. Th e patient underwent upper endoscopy that was normal and a colonoscopy that showed a few infl ammatory polyps in the colon and multiple infl ammatory polyps in the terminal ileum. Th ere was a large ileal polyp that intermittently prolapsed through the ileocecal valve (Figure 4a ). Double balloon colonoscopy with retrograde enteroscopy showed multiple large polypoid lesions in the ileum forming a mass-like lesion (Figures 4b and 4c) . It was determined that due to the large polyp burden and mass-like eff ect, endoscopic resection of the polyps would not be possible. It was thought that the patient was likely experiencing intermittent bowel obstruction and bleeding from these lesions and was therefore referred for surgical resection of the polypoid mass.
Small bowel and colon biopsies showed the presence of hamartomatous/juvenile polyps. Th e fragments of tissue showed surface ulceration and an underlying infl ammatory infi ltrate (Figure 5a) . Th e deeper portions of the glands demonstrated crowded and hyperchromatic nuclei (fi rst thought to be adenomatous change), but there was relatively normal maturation towards the surface, suggesting a reactive process. Th ese were thought to most likely represent hamartomatous polyps with regenerative changes.
Th e patient then underwent right hemicolectomy with resection of the aff ected portion of her small bowel. Approximately 2 feet of terminal ileum and right colon were resected. Histologic sections showed similar fi ndings to that seen on biopsy, with hamartomatous polyps containing regenerative changes. Some areas contained more worrisome architectural features with complex cribriforming of glands (high-grade dysplasia) and focal gland breakdown, suspicious for early invasion (Figure 5b ). Rare foci showed more defi nitive evidence of invasion with small clusters and single cells extending into the lamina propria. No invasion was seen beyond the lamina propria, consistent with an early "intramucosal adenocarcinoma." Additionally, there were 22 benign lymph nodes, along with the incidental fi nding of enteritis cystica profunda (Figure 5c ). Multiple hemangiomas and vascular changes (Figure 5d) , consistent with the clinical history of HHT, were also present. Th e patient did well following surgery and has been referred to a genetic counselor for testing and follow-up.
DISCUSSION
JP-HHT syndrome is a combination of two autosomal dominant disorders secondary to a mutation in one gene, SMAD4. Both syndromes alone are rare, with an incidence of 1 in 100,000 for JPS (12) and 1 in 1300 to 1 in 40,000 for HHT based on ethnicity (4, 13) . Approximately 50% to 60% of patients with JPS will have SMAD4 mutations (14) , while only 20% of patients with HHT will share this same SMAD4 mutation (6). Th erefore, the incidence of JP-HHT syndrome as a result of the SMAD4 mutation is exceedingly rare.
Patients with JP often present in childhood with multiple hamartomatous (juvenile) polyps throughout the gastrointestinal tract (1, 2). Th ese polyps are primarily found in the colorectum, but they can occur throughout the gastrointestinal tract from the stomach to rectum (2) . Th e polyps are usually benign, but these patients have an increased risk of gastrointestinal cancer, ranging from 9% to 50%, which can involve the stomach, upper gastrointestinal tract, and pancreas (1, 2, 15) . HHT involves vascular dysplasia in multiple organs including the skin, oral and nasal mucosa telangiectasias, and AVMs of the lungs, liver, brain, and gastrointestinal tract (16) (17) (18) . Patients often experience excessive bleeding from the nose or gastrointestinal tract, with age-related penetrance (penetrance increases with age, 80% to 90% with recurrent epistaxis by age 21). Lung lesions can lead to hypoxemia, orthodeoxia, or Brain AVMs can cause strokes or spinal hemorrhage. Liver lesions can lead to high-output heart failure, portal hypertension, or biliary disease due to biliary ischemia (19) . To date, the only treatment available for these severe hepatic forms of HHT is orthotopic liver transplantation; however, a recent study examined the effi cacy of bevacizumab in severe hepatic forms of HHT associated with high cardiac output (20) . Th ey found that treatment with bevacizumab resulted in a decrease in cardiac output and reduced the duration and number of episodes of epistaxis. Th us, other options to liver transplantation may be available. Our patient had several characteristics of both JP and HHT, including nosebleeds, clubbing of the fi ngers and toes, and multiple hamartomatous polyps of the colon and small bowel, with a focal area of adenocarcinoma in her resected bowel.
Patients with JPS have a mutation in either the BMPR1A gene or SMAD4 gene, while patients with HHT have a mutation in either the ENG, ALK1, or SMAD4 genes or in another locus (21) . SMAD4, the common gene in these two disorders, serves as a tumor suppressor gene by involvement in the transforming growth factor-␤ growth inhibitory pathway (22) .
Our patient was referred for genetic testing for the SMAD4 mutation. Of interest, both her father and paternal grandfather had a history of colon polyps, AVMs, and nosebleeds ( Figure 1) . Th is suggests that the patient's putative SMAD4 mutation was inherited paternally. Patients diagnosed with JPS or HHT may have hidden features of the other disorder. Th ese undiscovered features often manifest themselves with extreme consequences. Th erefore, any patient who has features of either JPS or HHT should have genetic screening for the SMAD4 mutation and be thoroughly examined for corresponding clinical pathology (6), so they can start the appropriate screening regimens. Th ese include annual testing for anemia, screening for pulmonary AVMs by pulse oximetry every 1 to 2 years in the fi rst decade of life and every 5 years by contrast echocardiogram thereafter, and antibiotic prophylaxis as a preventive measure for secondary complications if pulmonary AVMs are suspected for dental or invasive procedures, as well as a fi lter on intravenous lines. Additionally, screening with colonoscopy and upper endoscopy should begin by age 15, or earlier if symptomatic. If not, critical pathologies in the patient may be missed, resulting in unwanted patient outcomes. Finally, if the combined JP-HHT syndrome is known to exist in a family, targeted mutation testing specifi c to the proband's mutation is indicated for at-risk family members in the fi rst two decades of life to implement the proper surveillance algorithms as described. Th e most cost-eff ective approach is to fi rst test and identify the mutation in the proband, permitting targeted testing specifi c for the mutation in at-risk relatives. Th e targeted analysis is less expensive than the initial search for the mutation, which is most likely to be detected in the known affected family member. A genetic counseling referral can assist in educating the patient and family members regarding testing and implications. Moreover, the genetic counselor can serve as a liaison for referrals to the appropriate personnel for follow-up.
